Discover our new line of three complementary food supplements designed to provide targeted nutritional support throughout the GLP 1 therapeutic journey, from the initial stages and treatment maintenance to the period following discontinuation.
The event provided an excellent opportunity to meet current and potential partners, explore new business opportunities and discuss future collaborations across international markets.
As Cor.Con. International continues to expand its international footprint, face-to-face meetings remain an important part of our approach to building strong, long-term partnerships and developing new opportunities in the healthcare sector.
Epilamba Junior by Cor.Con. International has been shortlisted as a finalist for the CPHI Pharma Awards 2026 in the Finished Formulation category.
Read the article